SFJ Pharmaceuticals

SFJ Pharmaceuticals

Robert DeBenedetto founded SFJ Pharmaceuticals in 2009, with initial capital from Clarus Funds and Abingworth Ventures. The firm operates as a joint venture between Blackstone Life Sciences and Abingworth, providing strategic funding and clinical development resources to biotech and pharma partners. SFJ's investment model funds 100% of clinical trials for partnered assets, assuming all regulatory risk. The firm targets oncology and other therapeutic areas, deploying capital across phases of development. Notable partnerships include Lenvatinib (Eisai), Mylotarg (Pfizer), and Empaveli (Apellis), each achieving regulatory approvals in the US, EU, Japan, and China. The firm also collaborates with PhaseBio and Nektar Therapeutics on co-development deals. Geographic footprint covers the US, Japan, China, and the EU. SFJ reports $4.5 billion in total deal value and over 18 partnerships as of 2025. The firm's primary investors include Blackstone Life Sciences and Abingworth Ventures, which have raised $2.5 billion in life science funds. The firm operates out of Pleasanton, California, with no additional offices publicly listed. Recent activity includes continuing partnerships with Apellis and PhaseBio for clinical-stage assets. SFJ's structural differentiator is its risk-based co-development model that bears 100% of clinical trial costs and regulatory risk — a hybrid of asset manager and development CRO. This allows partners to avoid dilution and bridge assets to readouts, while SFJ captures returns through tailored payback structures tied to regulatory milestones.